Edgemont Capital Partners served as exclusive financial advisor to Compass Research in the company’s sale to Bioclinica.

The sale of Compass Research is the 13th clinical research site company transaction closed by Edgemont and the 12th transaction for a CNS-focused outsourced pharmaceutical services company.

“The highly fragmented clinical research site services market is consolidating rapidly. Leading companies in the industry, particularly those with strong clinical and therapeutic expertise such as Compass Research, are in increasingly high demand by a growing number of strategic and financial buyers. These acquirers are seeking to capitalize on benefits of scale for site services given evolving clinical trials business dynamics and in order to address the acute challenges of subject recruitment. As a result, we expect industry consolidation to accelerate,” said David Blume, managing director and head of Edgemont’s Pharmaceutical Services Group.

Orlando, FL-based Compass Research conducts early and late stage clinical research studies for global and mid-sized pharmaceutical and biotech sponsors.

Bioclinica is a specialty services provider that utilizes expertise and technology to create clarity in the clinical trial process.

Edgemont Capital Partners is an independent investment banking firm focused on the merger and acquisitions advisory and financing needs of healthcare companies.